<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
	<channel>
		<title>Synaptic Transmissions</title>
		<description>Central Latency Reduction</description>
		<link></link>
		<atom:link href="/rss-feed.xml" rel="self" type="application/rss+xml" />
		
			<item>
				<title>Comparing effectiveness of newer antiseizure medications.</title>
				
					<dc:creator>Habakuk Hain</dc:creator>
				
				
					<description>&lt;p&gt;&lt;strong&gt;Problem&lt;/strong&gt;: Direct comparative effectiveness data among newer antiseizure medications in drug-resistant focal epilepsy has been limited. This is largely because prospective studies are hard to design and to conduct ethically. Withholding treatment in placebo-controlled trials can often times not be done ethically and for most patients eligible to enrol in such studies, seizures are relatively rare events, leading to a large sample sizes for sufficient statistical power.&lt;/p&gt;
</description>
				
				<pubDate>Sun, 22 Feb 2026 05:00:00 +0000</pubDate>
				<link>/posts/transmission-4/</link>
				<guid isPermaLink="true">/posts/transmission-4/</guid>
			</item>
		
			<item>
				<title>MS progression despite high-efficacy therapy.</title>
				
					<dc:creator>Habakuk Hain</dc:creator>
				
				
					<description>&lt;p&gt;&lt;strong&gt;Problem&lt;/strong&gt;: There is a paradigmatic shift in MS care on its way as evidence is accumulating that using high-efficacy therapies (HET) in early stages of the disease prevents relapses and decreases evidence of disease activity on sequential MRI scans. Whether high-efficacy MS therapies can prevent progression independent of relapse and MRI activity (PIRMA) is an open questions.&lt;/p&gt;
</description>
				
				<pubDate>Sat, 21 Feb 2026 15:04:48 +0000</pubDate>
				<link>/posts/transmission-3/</link>
				<guid isPermaLink="true">/posts/transmission-3/</guid>
			</item>
		
			<item>
				<title>Recombinant zoster vaccine and dementia risk.</title>
				
					<dc:creator>Habakuk Hain</dc:creator>
				
				
					<description>&lt;p&gt;&lt;strong&gt;Problem&lt;/strong&gt;: There is converging evidence that live zoster vaccines reduce dementia risk, but comparable evidence is lacking for the recombinant zoster vaccine (RZV).&lt;/p&gt;
</description>
				
				<pubDate>Sat, 21 Feb 2026 00:00:00 +0000</pubDate>
				<link>/posts/transmission-2/</link>
				<guid isPermaLink="true">/posts/transmission-2/</guid>
			</item>
		
			<item>
				<title>ALS Roundup</title>
				
					<dc:creator>Habakuk Hain</dc:creator>
				
				
					<description>&lt;p&gt;There is a lot of movement in the ALS space. Some recent advances include insight into the pathomechanism of one genetic variant and reports of the first successful treatment with no evidence of disease progression of another genetic variant.&lt;/p&gt;
</description>
				
				<pubDate>Sat, 21 Feb 2026 00:00:00 +0000</pubDate>
				<link>/posts/convergence-1/</link>
				<guid isPermaLink="true">/posts/convergence-1/</guid>
			</item>
		
			<item>
				<title>Complement deposition in NMOSD, MOGAD, and MS.</title>
				
					<dc:creator>Habakuk Hain</dc:creator>
				
				
					<description>&lt;p&gt;&lt;strong&gt;Problem&lt;/strong&gt;: The role of complement in MOGAD and MS pathogenesis remains unclear despite established complement involvement in NMOSD. This is particularly interesting since we have effective complement inhibitors as a potential therapeutic option.&lt;/p&gt;
</description>
				
				<pubDate>Tue, 17 Feb 2026 00:00:00 +0000</pubDate>
				<link>/posts/transmission-1/</link>
				<guid isPermaLink="true">/posts/transmission-1/</guid>
			</item>
		
	</channel>
</rss>
